Literature DB >> 9369853

Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation.

E Vogt1, A K Ng, N S Rote.   

Abstract

OBJECTIVE: Trophoblast differentiation is associated with externalization of phosphatidylserine from the inner to the outer surface of the plasma membrane. In this study we tested the hypothesis that concurrent externalization and binding of annexin-V blocks the phosphatidylserine-rich surface from acting as a site for activation of coagulation and that antiphospholipid antibodies lead to a procoagulant state by preventing annexin-V binding. STUDY
DESIGN: A choriocarcinoma model of trophoblast differentiation, forskolin-activated BeWo cells and immunoperoxidase techniques were used to determine surface and cytoplasmic localization of annexin-V related to differentiation. Monoclonal immunoglobulin M antibodies against phosphatidylserine- and cardiolipin-dependent antigens were used to determine the effects of antiphospholipid antibodies on annexin-V localization and on the binding of prothrombin to the BeWo surface.
RESULTS: During differentiation BeWo cells externalized phosphatidylserine and increased the expression of surface annexin-V. Monoclonal antibody against phosphatidylserine removed annexin-V from the BeWo surface and increased binding of prothrombin.
CONCLUSION: Antiphosphatidylserine antibody induces sites for prothrombin binding on the surface of a BeWo model of trophoblast, most likely by removing annexin-V. This mechanism could explain the frequent observation of increased thrombosis at the maternal-fetal interface in miscarriages associated with antiphospholipid antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369853     DOI: 10.1016/s0002-9378(97)70302-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Phosphatidylserine as an anchor for plasminogen and its plasminogen receptor, histone H2B, to the macrophage surface.

Authors:  R Das; E F Plow
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

2.  Resistance to annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome.

Authors:  Beverley J Hunt; Xiao-Xuan Wu; Bas de Laat; Alan A Arslan; Sara Stuart-Smith; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-15       Impact factor: 8.661

3.  Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.

Authors:  Xiao-Xuan Wu; Seth Guller; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-24       Impact factor: 8.661

4.  Antiphosphatidyl serine autoantibodies and premature coronary events.

Authors:  Hisham Y M Ali; Zainalabideen A Abdullah
Journal:  Sultan Qaboos Univ Med J       Date:  2007-12

Review 5.  The pathogenic role of annexin-V in the antiphospholipid syndrome.

Authors:  J H Rand
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

6.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

Review 7.  Reimagining the antiphospholipid syndrome, an enigmatic thrombophilic disorder, through the looking glass of microscopic imaging.

Authors:  Jacob H Rand; Douglas J Taatjes
Journal:  Histochem Cell Biol       Date:  2018-08-18       Impact factor: 4.304

Review 8.  The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome.

Authors:  Oscar Cabrera-Marante; Edgard Rodríguez de Frías; Manuel Serrano; Fernando Lozano Morillo; Laura Naranjo; Francisco J Gil-Etayo; Estela Paz-Artal; Daniel E Pleguezuelo; Antonio Serrano
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.